Québec City, July 15, 2014 – TSO3 Inc. (TSX: TOS) (“TSO3” or the “Corporation”) an innovator in sterilization technology for medical devices in healthcare settings, today announced that pursuant to the regulatory submission filed on May 2, 2014 with the US Regulatory Authorities, for the STERIZONE® VP4 Sterilizer, the Company has received an Additional Information (AI) Request from the Regulators. At present the Company and the Agency are actively involved in discussions in connection with that request.
“This type of dialogue is common in the clearance process.” stated Mr. R.M. (Ric) Rumble, President and CEO. “Due to the regulatory context, and the nature of these discussions, no details will be released at this time. The Company remains comfortable working through the process with the Regulators”, concluded Mr. Rumble.
TSO3, founded in Québec City in 1998, specializes in the research and development of innovative, high-performance medical instrument sterilization technology with high commercial potential. TSO3 designs products for sterile processing areas in the hospital environment and offers an advantageous replacement solutions to other low temperature sterilization processes currently used in hospitals.
For more information about TSO3, visit the Company’s Web site at www.tso3.com
The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of any financing undertaken by TSO3) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other risks and uncertainties.
The TSX has neither approved nor disapproved the information contained herein and accepts no responsibility for it.
-30-Back to Posts